These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28850133)

  • 1. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].
    Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Arion VB
    Inorg Chem; 2011 Aug; 50(16):7690-7. PubMed ID: 21739939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osmium(III) analogues of KP1019: electrochemical and chemical synthesis, spectroscopic characterization, X-ray crystallography, hydrolytic stability, and antiproliferative activity.
    Kuhn PS; Büchel GE; Jovanović KK; Filipović L; Radulović S; Rapta P; Arion VB
    Inorg Chem; 2014 Oct; 53(20):11130-9. PubMed ID: 25290960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
    Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity.
    Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Heffeter P; Berger W; Arion VB
    J Inorg Biochem; 2012 Aug; 113():47-54. PubMed ID: 22687494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(II)-mediated coupling reaction of acetonitrile with 1H-indazole.
    Reisner E; Arion VB; Rufińska A; Chiorescu I; Schmid WF; Keppler BK
    Dalton Trans; 2005 Jul; (14):2355-64. PubMed ID: 15995743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism elucidation of the cis-trans isomerization of an azole ruthenium-nitrosyl complex and its osmium counterpart.
    Gavriluta A; Büchel GE; Freitag L; Novitchi G; Tommasino JB; Jeanneau E; Kuhn PS; González L; Arion VB; Luneau D
    Inorg Chem; 2013 Jun; 52(11):6260-72. PubMed ID: 23675748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
    Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
    Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the binding of cis/trans-[MCl4(1H-indazole)(NO)](-) (M = Ru, Os) complexes to human serum albumin.
    Dömötör O; Rathgeb A; Kuhn PS; Popović-Bijelić A; Bačić G; Enyedy EA; Arion VB
    J Inorg Biochem; 2016 Jun; 159():37-44. PubMed ID: 26908285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electronic structures of ruthenium and osmium complexes of 9,10-phenanthrenequinone.
    Biswas MK; Patra SC; Maity AN; Ke SC; Adhikary ND; Ghosh P
    Inorg Chem; 2012 Jun; 51(12):6687-99. PubMed ID: 22663598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Novak MS; Büchel GE; Keppler BK; Jakupec MA
    J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
    van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
    J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Effects of Ir(III)-2
    Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
    Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
    Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1
    Richert M; Trykowski G; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Sobczak JW; Biniak S
    Dalton Trans; 2020 Dec; 49(46):16791-16800. PubMed ID: 33174575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NO Releasing and Anticancer Properties of Octahedral Ruthenium-Nitrosyl Complexes with Equatorial 1 H-Indazole Ligands.
    Orlowska E; Babak MV; Dömötör O; Enyedy EA; Rapta P; Zalibera M; Bučinský L; Malček M; Govind C; Karunakaran V; Farid YCS; McDonnell TE; Luneau D; Schaniel D; Ang WH; Arion VB
    Inorg Chem; 2018 Sep; 57(17):10702-10717. PubMed ID: 30106571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.